Holen Sie sich die Stockscreener-App
2.80
0.54%
0.02
Schlusskurs vom Vortag:
$2.78
Offen:
$2.75
24-Stunden-Volumen:
1.24M
Relative Volume:
0.36
Marktkapitalisierung:
$742.41M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-10.00
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-5.25%
1M Leistung:
-5.25%
6M Leistung:
+52.73%
1J Leistung:
+111.74%
1-Tages-Spanne:
$2.70
$2.84
1-Wochen-Bereich:
$2.69
$3.02
52-Wochen-Spanne:
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.80 | 737.10M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
143.28 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.165 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
434.04 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Zacks Investment Research
Real time breakdown of Akebia Therapeutics Inc. stock performanceMarket Movement Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
Applying Elliott Wave Theory to Akebia Therapeutics Inc.2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
Is this a good reentry point in Akebia Therapeutics Inc.July 2025 Recap & Long-Term Safe Investment Ideas - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth fundsJuly 2025 Action & Community Consensus Picks - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockInsider Selling & Weekly Top Gainers Trade List - newser.com
Applying chart zones and confluence areas to Akebia Therapeutics Inc.Quarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
What to expect from Akebia Therapeutics Inc. in the next 30 daysCPI Data & Fast Gaining Stock Strategy Reports - newser.com
Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year - Markets Mojo
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Movers & Daily Volume Surge Trade Alerts - newser.com
Can technical indicators confirm Akebia Therapeutics Inc.’s reversalJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
What machine learning models say about Akebia Therapeutics Inc.Quarterly Trade Summary & High Win Rate Trade Tips - newser.com
How Akebia Therapeutics Inc. stock performs in interest rate cycles2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Why Akebia Therapeutics Inc. (AX9) stock is a strong buy callQuarterly Portfolio Summary & Smart Allocation Stock Tips - newser.com
How Akebia Therapeutics Inc. stock reacts to inflationary pressuresTrade Ideas & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:00:40 - newser.com
Can Akebia Therapeutics Inc. (AX9) stock resist broad market declinesQuarterly Trade Summary & AI Powered Market Entry Ideas - newser.com
How Akebia Therapeutics Inc. (AX9) stock moves in volatile trading sessions2025 Institutional Moves & Daily Chart Pattern Signals - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st
What drives Akebia Therapeutics Inc stock priceInsider Buying Signals & Free Daily Market Summary and Trend Reports - earlytimes.in
Published on: 2025-10-03 06:28:34 - newser.com
Is Akebia Therapeutics Inc. stock poised for growthRate Hike & Weekly High Conviction Ideas - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boom2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Leading vs lagging indicators on Akebia Therapeutics Inc. performanceJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Is Akebia Therapeutics Inc. stock entering bullish territoryJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why ETFs are accumulating Akebia Therapeutics Inc. (AX9) stockProfit Target & Fast Exit/Entry Strategy Plans - newser.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):